Dr. Benjamin Derman
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 197
Licensed in Illinois since 2015, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Northwestern University Feinberg Medical School
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036139543 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Swedish Hospital Chicago, IL
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 197
- Services billed
- 1,108
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 305 | 122 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 213 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 25 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 14 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | 11 |
| Hospital discharge day management, more than 30 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 280 |
| Lenalidomide | 111 |
| Pomalyst (pomalidomide) | 86 |
| Acyclovir Other prescribers in Chicago, IL | 74 |
| Eliquis (apixaban) Other prescribers in Chicago, IL | 51 |
| Xarelto (rivaroxaban) Other prescribers in Chicago, IL | 27 |
| Amlodipine Besylate Other prescribers in Chicago, IL | 22 |
| Duloxetine Hcl Other prescribers in Chicago, IL | 20 |
| Dexamethasone Other prescribers in Chicago, IL | 18 |
| Prednisone Other prescribers in Chicago, IL | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 30 payments worth $37,106 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $20,907 |
|---|---|
| Janssen Scientific Affairs, LLC | $4,390 |
| Legend Biotech USA Inc. | $4,286 |
| Genzyme Corporation | $4,250 |
| Janssen Global Services, LLC | $2,905 |
| Adaptive Biotechnologies Corporation | $173 |
| Janssen Biotech, Inc. | $135 |
| AstraZeneca Pharmaceuticals LP | $60.00 |
| Consulting Fee | $32,250 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,250 |
| Food and Beverage | $606 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Apr 25, 2025 | Consulting Fee | $6,600 |
| Genzyme Corporation Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $4,250 |
| Legend Biotech USA Inc. Sep 25, 2025 | Consulting Fee CARVYKTI · Oncology | $2,760 |
| E.r. Squibb & Sons, L.l.c. Apr 29, 2025 | Consulting Fee | $2,200 |
| E.r. Squibb & Sons, L.l.c. May 19, 2025 | Consulting Fee | $2,200 |
| E.r. Squibb & Sons, L.l.c. Jun 27, 2025 | Consulting Fee | $2,200 |
| Janssen Global Services, LLC Dec 6, 2025 | Consulting Fee CARVYKTI · Oncology | $1,763 |
| Janssen Scientific Affairs, LLC Feb 3, 2025 | Consulting Fee | $1,650 |
| Legend Biotech USA Inc. Nov 24, 2025 | Consulting Fee CARVYKTI · Oncology | $1,380 |
| E.r. Squibb & Sons, L.l.c. Jun 23, 2025 | Consulting Fee | $1,375 |
All 22 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Global Services, LLC Dec 6, 2025 | Consulting Fee CARVYKTI · Oncology | $1,763 |
| Legend Biotech USA Inc. Nov 24, 2025 | Consulting Fee CARVYKTI · Oncology | $1,380 |
| Legend Biotech USA Inc. Sep 25, 2025 | Consulting Fee CARVYKTI · Oncology | $2,760 |
| Genzyme Corporation Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $4,250 |
| E.r. Squibb & Sons, L.l.c. Jul 11, 2025 | Consulting Fee | $1,100 |
| E.r. Squibb & Sons, L.l.c. Jun 27, 2025 | Consulting Fee | $2,200 |
| E.r. Squibb & Sons, L.l.c. Jun 23, 2025 | Consulting Fee | $1,375 |
| E.r. Squibb & Sons, L.l.c. Jun 11, 2025 | Consulting Fee | $550 |
| E.r. Squibb & Sons, L.l.c. May 19, 2025 | Consulting Fee | $2,200 |
| Janssen Global Services, LLC Apr 30, 2025 | Consulting Fee TECVAYLI · Oncology | $1,058 |
| E.r. Squibb & Sons, L.l.c. Apr 29, 2025 | Consulting Fee | $2,200 |
| E.r. Squibb & Sons, L.l.c. Apr 25, 2025 | Consulting Fee | $6,600 |
| E.r. Squibb & Sons, L.l.c. Apr 17, 2025 | Consulting Fee | $825 |
| Janssen Scientific Affairs, LLC Mar 31, 2025 | Consulting Fee | $550 |
| E.r. Squibb & Sons, L.l.c. Mar 6, 2025 | Consulting Fee | $1,100 |
| E.r. Squibb & Sons, L.l.c. Feb 21, 2025 | Consulting Fee | $1,100 |
| E.r. Squibb & Sons, L.l.c. Feb 12, 2025 | Consulting Fee | $550 |
| E.r. Squibb & Sons, L.l.c. Feb 7, 2025 | Consulting Fee | $550 |
| Janssen Scientific Affairs, LLC Feb 3, 2025 | Consulting Fee | $1,650 |
| E.r. Squibb & Sons, L.l.c. Jan 28, 2025 | Consulting Fee | $550 |
| Janssen Scientific Affairs, LLC Jan 15, 2025 | Consulting Fee | $1,100 |
| Janssen Scientific Affairs, LLC Jan 14, 2025 | Consulting Fee CARVYKTI · Oncology | $1,090 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $1,506,822 in research payments for these studies, mostly to the institutions running them.
- Phaase II study of belantamab mafodotin in combination with carfilzomib, pomalidomide, and dexamethasone (KPd) in patients with relapsed multiple myelom
Amgen Inc. - A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
AstraZeneca Pharmaceuticals LP - A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Beone Medicines Ltd. · Recruiting · NCT04973605 - Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Novartis Pharmaceuticals Corporation - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
Celgene Corporation - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.